Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical and functional data for patients (n = 27) with interstitial pulmonary fibrosis (IPF)

From: [18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis

Characteristics
 Age (years) 65.3 ± 12.4
 Duration of disease (years) 2.9 ± 2.7
 Sex ratio (M/F), no. 22/5
 Mortality (%) 44% (12/27)
 Survival (years) 1.5 ± 1.2
 Duration of follow-up (years) 3.4 ± 1.2
Smoking status, n (pack-years)
 Current smoker 4 (45 ± 5)
 Former smoker 12 (27 ± 12)
 Never smoker 11
Lung function tests
 FVC (L) 2.3 ± 0.9
 FVC (% predicted) 71 ± 26
 DLCO (% predicted) 41 ± 16
 Distance traveled during 6MWT (meters) (meters) (meters)=21) 457 ± 76
 PaO2 (mmHg) 69.2 ± 9.1
 PaCO2 (mmHg) 36.8 ± 2.6
 Bronchoalveolar lavage cytology (n = 19) Cellularity (x103/mL) 263 ± 19
 Macrophages (%) 62.0 ± 4.6
 Lymphocytes (%) 9.3 ± 1.6
 Neutrophils (%) 22.2 ± 5.0
 Eosinophils (%) 2.5 ± 1.6
  1. Data are mean ± SD unless indicated